ACTIVE_NOT_RECRUITING

Impact of Different Carbohydrate Feedings on a Hydrogen Breath Curve and Self-reported Gastrointestinal Complaints

Conditions

Quality of Life participants healthy subjects women men malabsorption syndrome

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

GI distress is widely prevalent among athletes, ranging from 30 to 90% in recreationally and professionally active athletes. As the recipient of nutrients, the gastrointestinal (GI) tract plays an important role in athleticism. The following pilot project aims to better understand if a fructose load after hiking under heat stress will result in a meaningful hydrogen breath elevation as a marker for malabsorption in healthy participants, and if supplementation of a multi-ingredient fermented whey supplement will result in a different hydrogen breath response rate after a heat stress hiking test.

Official Title

Hydrogen Breath Test Results After Consuming Fructose at Baseline and After Protein Supplementation

Quick Facts

Study Start:2024-10-03

Study Completion:2026-05-30

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:ACTIVE_NOT_RECRUITING

Study ID

NCT06648967

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 60 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:Yes

Standard Ages:ADULT

Inclusion Criteria	Exclusion Criteria
* Healthy subjects living in the United States. * Women/Men aged between 18-60 years (50-50%). * BMI value between ≥18.5 and ≤ 30 kg/m2. * No physical limitations (i.e., able to perform all activities associated with daily living in an independent manner). * Written informed consent. * Completed PAR-Q+ without any "yes" responses. * If currently using chronically or intermittently, willing to stop taking pre- and probiotics beginning 1 month prior to and throughout data collection. * If currently using chronically or intermittently, willing to stop using laxatives or fiber supplements, antacids and prokinetics beginning 1 month prior to and throughout data collection.	* Smoking. * Clinical or self-perceived lactose intolerance. * Clinical or self-perceived milk protein allergy. * Diagnosed GI tract disorders or diseases. * Musculoskeletal disorders. * Diagnosed metabolic disorders (such as diabetes). * Use of any medications known to affect protein metabolism (i.e., corticosteroids, non-steroidal anti-inflammatories, or prescribed acne medications). * Chronic use of gastric acid suppressing medication or anti-coagulants. * Chronic use of anti-inflammatory medication. * Unwilling to stop taking pre- and probiotics beginning 1 month prior to and throughout data collection. * Unwilling to stop using laxatives or fiber supplements, antacids and prokinetics beginning 1 month prior to and throughout data collection.

Inclusion Criteria

Exclusion Criteria

* Healthy subjects living in the United States.
* Women/Men aged between 18-60 years (50-50%).
* BMI value between ≥18.5 and ≤ 30 kg/m2.
* No physical limitations (i.e., able to perform all activities associated with daily living in an independent manner).
* Written informed consent.
* Completed PAR-Q+ without any "yes" responses.
* If currently using chronically or intermittently, willing to stop taking pre- and probiotics beginning 1 month prior to and throughout data collection.
* If currently using chronically or intermittently, willing to stop using laxatives or fiber supplements, antacids and prokinetics beginning 1 month prior to and throughout data collection.

* Smoking.
* Clinical or self-perceived lactose intolerance.
* Clinical or self-perceived milk protein allergy.
* Diagnosed GI tract disorders or diseases.
* Musculoskeletal disorders.
* Diagnosed metabolic disorders (such as diabetes).
* Use of any medications known to affect protein metabolism (i.e., corticosteroids, non-steroidal anti-inflammatories, or prescribed acne medications).
* Chronic use of gastric acid suppressing medication or anti-coagulants.
* Chronic use of anti-inflammatory medication.
* Unwilling to stop taking pre- and probiotics beginning 1 month prior to and throughout data collection.
* Unwilling to stop using laxatives or fiber supplements, antacids and prokinetics beginning 1 month prior to and throughout data collection.

Contacts and Locations

Study Locations (Sites)

Health Futures Center

Phoenix, Arizona, 85054

United States

Collaborators and Investigators

Sponsor: Arizona State University

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-10-03

Study Completion Date2026-05-30

Study Record Updates

Study Start Date2024-10-03

Study Completion Date2026-05-30

Terms related to this study

Keywords Provided by Researchers

participants
healthy subjects
women
men
malabsorption syndrome

Additional Relevant MeSH Terms

Quality of Life